[TREATMENT OF HUMAN HEPATIC FASCIOLASIS WITH TRICLABENDAZOLE]

Rev Gastroenterol Peru. 1999 Jul-Sep;19(3):216-220.
[Article in Spanish]

Abstract

This study has the purpose to evaluate the effect of triclabendazole over human fasciolasis produced by Fasciola hepatica. 70 patients with positive stools studies for fasciolasis were treated with 12 mg/kg/ day of triclabendazole for 2 days.The control stools tests were performed 15 and 45 days after the treatment was finished. Parasitologic negativitation of stools was found in 83% of those patients who recieved 1 cycle of treatment. 14% needed 2 cycles and 3% a third one.No important side effects were reported because of treatment. We conclude that triclabendazole is highly efficient and good against liver fasciolasis in humans.